GD2-CART01 is under clinical development by Bellicum Pharmaceuticals and currently in Phase I for Medulloblastoma. According to GlobalData, Phase I drugs for Medulloblastoma have a 66% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how GD2-CART01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GD2-CART01 overview
GD2-CART01 is under development for the treatment of refractory and relapsed neuroblastoma, medulloblastoma, high-grade glioma, diffuse intrinsic pontine glioma and central nervous system tumor. It is administered through intravenous and parenteral route. The therapy comprises of T cells genetically modified through gammaretroviral transduction to express a chimeric antigen receptor (CAR) targeting the cells expressing ganglioside GD2 antigen and incorporated with safety switch. It is being developed based on caspaCIDe and CID technology. The technology enables control of caspase-9 signaling.
The drug candidate was also under development for the treatment of osteosarcoma, rhabdomyosarcoma and melanoma.
Bellicum Pharmaceuticals overview
Bellicum Pharmaceuticals (Bellicum) is a clinical-stage biopharmaceutical company. It primarily focuses on the development and commercialization of novel cellular immunotherapies for various forms of cancer. The company’s product candidates include BPX-601 and BPX-603, that are designed to be more efficacious CAR-T cell products capable of overriding key immune inhibitory mechanisms. Bellicum’s GoCAR technology builts a enhance effector cell proliferation and functional persistence and is designed to enlist wider immune cell engagement to target resistant tumor cells. Its therapies are primarily targeted towards cancer patients, aiming to provide more effective treatment options. The company operates in the US. Bellicum is headquartered in Houston, Texas, the US.
For a complete picture of GD2-CART01’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
